Biodesix, Inc.
BDSX
$0.8622
$0.01221.44%
| Weiss Ratings | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.22 | |||
| Price History | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 3.67% | |||
| 30-Day Total Return | -4.25% | |||
| 60-Day Total Return | -36.13% | |||
| 90-Day Total Return | -47.10% | |||
| Year to Date Total Return | -41.74% | |||
| 1-Year Total Return | -42.52% | |||
| 2-Year Total Return | -51.56% | |||
| 3-Year Total Return | -60.45% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -58.33% | |||
| 52-Week Low % Change | 33.86% | |||
| Price | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $2.04 | |||
| 52-Week Low Price | $0.64 | |||
| 52-Week Low Price (Date) | Mar 04, 2025 | |||
| 52-Week High Price (Date) | Aug 30, 2024 | |||
| Valuation | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 123.65M | |||
| Enterprise Value | 159.38M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.39 | |||
| Earnings Per Share Growth | -56.19% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.90 | |||
| Price/Book (Q) | 4.44 | |||
| Enterprise Value/Revenue (TTM) | 2.43 | |||
| Price | $0.86 | |||
| Enterprise Value/EBITDA (TTM) | -5.45 | |||
| Enterprise Value/EBIT | -4.61 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 146.30M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 303 417 0500 | |||
| Address | 919 West Dillon Road Louisville, CO 80027 | |||
| Website | www.biodesix.com | |||
| Country | United States | |||
| Year Founded | 2005 | |||
| Profitability | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -52.71% | |||
| Profit Margin | -66.83% | |||
| Management Effectiveness | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.79% | |||
| Return on Equity | -- | |||
| Income Statement | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 65.56M | |||
| Total Revenue (TTM) | 65.56M | |||
| Revenue Per Share | $0.45 | |||
| Gross Profit (TTM) | 50.96M | |||
| EBITDA (TTM) | -29.26M | |||
| EBIT (TTM) | -34.56M | |||
| Net Income (TTM) | -43.82M | |||
| Net Income Avl. to Common (TTM) | -43.82M | |||
| Total Revenue Growth (Q YOY) | 34.54% | |||
| Earnings Growth (Q YOY) | 6.31% | |||
| EPS Diluted (TTM) | -0.39 | |||
| EPS Diluted Growth (Q YOY) | 48.98% | |||
| Balance Sheet | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 31.41M | |||
| Cash Per Share (Q) | $0.21 | |||
| Total Current Assets (Q) | 44.02M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 27.86M | |||
| Current Ratio (Q) | 3.396 | |||
| Book Value Per Share (Q) | $0.19 | |||
| Total Assets (Q) | 102.74M | |||
| Total Current Liabilities (Q) | 12.96M | |||
| Total Debt (Q) | 62.50M | |||
| Total Liabilities (Q) | 74.89M | |||
| Total Common Equity (Q) | 27.86M | |||
| Cash Flow | BDSX - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -5.56M | |||
| Cash from Financing (TTM) | 73.96M | |||
| Net Change in Cash (TTM) | 11.57M | |||
| Levered Free Cash Flow (TTM) | -43.44M | |||
| Cash from Operations (TTM) | -56.84M | |||
